Skip to main content
Article thumbnail
Location of Repository

Adjuvant-free immunization with hemagglutinin-Fc fusion proteins as an approach to influenza vaccines

By Silvia Loureiro, Junyuan Ren, Pongsathon Phapugrangkul, Camilo A. Colaco, Christopher R. Bailey, Holly Shelton, Eleonora Molesti, Nigel J. Temperton, Wendy S Barclay and Ian M. Jones


The hemagglutinins (HAs) of human H1 and H3 influenza viruses and avian H5 influenza virus were produced as recombinant fusion proteins with the human immunoglobulin Fc domain. Recombinant HA-human immunoglobulin Fc domain (HA-HuFc) proteins were secreted from baculovirus-infected insect cells as glycosylated oligomer HAs of the anticipated molecular mass, agglutinated red blood cells, were purified on protein A, and were used to immunize mice in the absence of adjuvant. Immunogenicity was demonstrated for all subtypes, with the serum samples demonstrating subtype-specific hemagglutination inhibition, epitope specificity similar to that seen with virus infection, and neutralization. HuFc-tagged HAs are potential candidates for gene-to-vaccine approaches to influenza vaccination. Copyright © 2011, American Society for Microbiology. All Rights Reserved

Topics: QR355
Year: 2011
DOI identifier: 10.1128/jvi.01241-10
OAI identifier:

Suggested articles


  1. (2006). A suite of parallel vectors for baculovirus expression. Protein Expr. doi
  2. (2007). An avian influenza H5N1 virus that binds to a human-type receptor. doi
  3. (2009). Antibodies designed as effective cancer vaccines. doi
  4. (2011). Antibody-based therapeutics to watch in doi
  5. (2007). Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370:580–589. doi
  6. (2008). Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. doi
  7. Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: possible role of the prolonged half-life of the immunogen. doi
  8. (1990). Directional cloning of cDNA using a selectable SfiI cassette. doi
  9. (2008). Dose translation from animal to human studies revisited. doi
  10. (2006). Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. doi
  11. (2010). Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS One 5:e12466. doi
  12. (2007). Epitope mapping of the hemagglutinin molecule of a highly pathogenic H5N1 influenza virus by using monoclonal antibodies. doi
  13. (2009). Fc-receptors and immunity to malaria: from models to vaccines. Parasite Immunol. doi
  14. (2009). Fine antigenic variation within H5N1 influenza virus hemagglutinin’s antigenic sites defined by yeast cell surface display. doi
  15. (2008). FluBlok, a recombinant hemagglutinin influenza vaccine. Influenza Other Respi. Viruses 2:211–219. doi
  16. (2009). Fusion-proteins as biopharmaceuticals—applications and challenges. doi
  17. (2006). Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. doi
  18. (2009). Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. doi
  19. (2007). Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity. doi
  20. (2007). Immunogenicity of the outer domain of a HIV-1 clade C gp120. Retrovirology 4:33. doi
  21. (2003). Improving baculovirus recombination. doi
  22. (2010). Influenza vaccines: from surveillance through production to protection. Mayo Clin. doi
  23. (2009). Influenza virus-like particles as pandemic vaccines. doi
  24. (2007). Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. doi
  25. (2008). Interaction of severe acute respiratory syndrome-coronavirus and NL63 coronavirus spike proteins with angiotensin converting enzyme-2. doi
  26. (2009). Mutations in H5N1 influenza virus hemagglutinin that confer binding to human tracheal airway epithelium. PLoS One 4:e7836. doi
  27. Neutralization escape mutants of type A influenza virus are readily selected by antisera from mice immunized with whole virus: a possible mechanism for antigenic drift. doi
  28. (2009). New strategies to overcome the drawbacks of currently available flu vaccines. doi
  29. (2010). posting date. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. doi
  30. (2007). Probing the receptor interactions of an H5 avian influenza virus using a baculovirus expression system and functionalised poly(acrylic acid) ligands. doi
  31. (2007). Production of a novel influenza vaccine using insect cells: protection against drifted strains. Influenza Other Respi. Viruses 1:35–40. doi
  32. (2008). Progress on baculovirus-derived influenza vaccines.
  33. (1996). Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. doi
  34. (2008). Recombinant vaccines for influenza virus. doi
  35. (2009). Recombinant vectors as influenza vaccines. doi
  36. (2010). The hemagglutin protein 158N glycosylation and receptor binding specificity synergistically affect antigenicity and immunogenicity of a live attenuated H5N1 A/Vietnam/1203/2004 vaccine virus in ferrets. doi
  37. (2009). Tumor necrosis factor-alpha antagonists: differential clinical effects by different biotechnological molecules.
  38. (2010). Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.